title: Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis.
authors.forename: C
authors.initials: C
authors.lastname: Rus
authors.forename: M
authors.initials: M
authors.lastname: Bazzan
authors.forename: A
authors.initials: A
authors.lastname: Palumbo
authors.forename: S
authors.initials: S
authors.lastname: Bringhen
authors.forename: M
authors.initials: M
authors.lastname: Boccadoro
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors; D013792:Thalidomide / Q000009:adverse effects* / Q000627:therapeutic use*; D013923:Thromboembolism / Q000139:chemically induced / Q000517:prevention & control; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents; D013792:Thalidomide